ArticleTranslational cancer research2025
Development and validation of a delta ultrasomics model for predicting treatment response to neoadjuvant chemotherapy in breast cancer.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Breast cancer is highly heterogeneous, it is imperative to determine patients who may benefit from neoadjuvant chemotherapy (NAC). This study aimed to develop and validate a delta radiomics-based model to predict the efficacy of neoadjuvant therapy in patients with breast cancer. Methods: A retrospective cohort of breast cancer patients undergoing NAC was analyzed, with ultrasomics features extracted from ultrasound images taken before treatment and after two cycles. The delta ultrasomics features were scored as 0 or 1 based on whether expression changed between posttreatment and baseline. Treatment response was assessed based on the residual cancer burden score. The Chi-squared test combined with least absolute shrinkage and selection operator (LASSO) regression was implemented for feature reduction. Six machine learning algorithms were then used for model development. The area under curve (AUC), calibration curve and decision curve analysis (DCA) were used to evaluate model performance. Results: A total of 669 breast cancer patients were included in this study, and 468 and 201 patients were randomly separated into training and test sets at a ratio of 7:3. For the 1,239 extracted radiomics features, the Chi-squared test followed by the LASSO model ultimately included 25 delta ultrasomics features for model construction. For the six machine learning models, the gradient boosting machine (GBM) had the highest average AUC value in the training and test sets, which had remarkable predictive ability in the training set [AUC =0.912, 95% confidence interval (CI): 0.887-0.936] and test set (AUC =0.872, 95% CI: 0.824-0.920). Calibration and DCA curves revealed that the eight prediction models all performed well in predicting the response to NAC. Conclusions: This study shows that delta ultrasomics model could be a valuable tool for predicting the response to NAC in breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.